# A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

> **NCT06262477** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 300 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** BIIB800
- **DRUG:** Actemra

## Key facts

- **NCT ID:** NCT06262477
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-02
- **Primary completion:** 2024-09-25
- **Final completion:** 2024-10-04
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06262477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06262477, "A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06262477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*